| Literature DB >> 33317595 |
G Sumann1, D Moens2, B Brink3, M Brodmann Maeder4, M Greene5, M Jacob6, P Koirala7, K Zafren8,9, M Ayala10, M Musi11, K Oshiro12, A Sheets13, G Strapazzon14,15, D Macias16, P Paal17.
Abstract
BACKGROUND: Multiple trauma in mountain environments may be associated with increased morbidity and mortality compared to urban environments.Entities:
Keywords: Advanced Trauma Life Support; analgesia; emergency medical services; first aid; haemorrhage; multiple trauma; shock, triage; wounds and injuries
Mesh:
Year: 2020 PMID: 33317595 PMCID: PMC7737289 DOI: 10.1186/s13049-020-00790-1
Source DB: PubMed Journal: Scand J Trauma Resusc Emerg Med ISSN: 1757-7241 Impact factor: 2.953
Classification scheme for grading evidence [6]
| Grade 1A | Strong recommendation, high quality evidence, benefits clearly outweigh risks and burden or vice versa |
| Grade 1B | Strong recommendation, moderate-quality evidence, benefits clearly outweigh risks and burdens or vice versa |
| Grade 1C | Strong recommendation, low-quality or very low-quality evidence, benefits clearly outweigh risks and burdens or vice versa |
| Grade 2A | Weak recommendation, high-quality evidence, benefits closely balanced with risks and burdens |
| Grade 2B | Weak recommendation, moderate-quality evidence, benefits closely balanced with risks and burdens |
| Grade 2C | Weak recommendation, low-quality or very low-quality evidence, uncertainty in the estimates of benefits, risks and burden; benefits, risk and burden may be closely balanced |
Fig. 1Treatment of multiple trauma in mountain environments algorithm. ABCDE; Airway, Breathing, Circulation, Disability, Exposure; IV; intravenous; IO; intraosseus; GCS: Glasgow Coma Scale; AVPU: Alert Voice Pain Unresponsive; TXA; tranexamic acid; SMR: spinal motion restriction; POCUS: point of care ultrasound; BP: blood pressure; SBP: systolic blood pressure; SpO2: oxygen saturation by pulse oximeter; MAP: mean arterial pressure; mmHg; millimetres of mercury
Patients who do not require immobilisation must meet all five of the following criteria [23]
| • awake and alert, | |
| • not intoxicated | |
| • no painful distracting injuries | |
| • no tenderness at the posterior midline along the cervical spine | |
| • no focal neurologic deficit |
All other patients require spinal motion restriction with stabilisation of the entire body, unless they have an ABCD instability, in which case minimal spinal motion restriction and immediate transfer may be preferred
Summary of haemostatic bandages, adapted from [105]. Gen denotes generation, RBCs red blood cells
| Manfacturer | Gen | Mechanism of action | Form | Application |
|---|---|---|---|---|
| Celox gauze, MedTrade Products Ltd., Crew, UK | 3rd | Cross-links RBCs to form mucoadhesive barrier | Chitosan rolled gauze Z-fold, 3 in. × 10 ft | Packed into wound, 3 min direct pressure |
| CeloxGauze Pro, HemCon Medical Technologies, Portland, OR | 3rd | Cross-links RBCs to form mucoadhesive barrier | Chitosan gauze Z-fold, 12 ft. length | Packed into wound, 2-5 min direct pressure |
| XStat, RevMedx Inc., Wilsonville, OR | 3rd | Cellulose sponges coated with chitosan to assist with a mucoadhesive barrier | 92 flat, circular, compressed mini sponges packaged in a 60 mL syringe applicator | The applicator has a small diameter insertion device available for use in wounds with narrow wound tracts |
Fluid resuscitation and adjuncts in haemorrhagic shock. AKI: acute kidney injury; CNS: central nervous system; HES: hydroxyethyl starch solution; ICU: intensive care unit; MA: metabolic acidosis; PRBCs: packed red blood cells; TBI: traumatic brain injury
| Agent | Advantages | Disadvantages | Notes |
|---|---|---|---|
0.9% Normal Saline (‘unbalanced’) | Readily available, familiar; compatible with most medications and blood products | Not ‘physiologic’ (high chloride load); excess administration leads to AKI and MA (2C) | Bolus to effect after bleeding controlled. (1A) |
| Ringer’s lactate/ acetate (‘balanced’); Plasmalyte | Readily available; ‘physiologic’ | Slightly hypotonic; excess administration worsens TBI (1C) | May reduce incidence of AKI and mortality in ICU. Bolus with control of bleed (1A) |
| Hypertonic saline solution | Low weight and volume (easier to transport); thermal stability; safe | May interfere with coagulation in patients with severe TBI | NaCl concentration > 0.9%; may expand volume, no long term survival benefit or improved CNS outcome vs. NaCl 0.9% |
Albumin, hydroxyethyl starch (HES), Dextran | Used as volume expander | Expensive; no proven mortality benefit. HES may increase harm in some subgroups. | Prehospital data still rare. HES may impair coagulation |
| May improve survival or physiology, for Hb < 7 g/dL; lyophilised plasma is used in damage control | Inconvenient in out-of-hospital environment; ARDS/ transfusion reactions | Used by few centres; PRBCs:plasma: platelets 1:1:1 or 2:1:1 (1B), or fibrinogen 0.5 g per unit PRBCs (1C) in hospital | |
| Use after adequate volume replacement (1C), Push-dose pressors simple; cardiac dysfunction: epinephrine | Does not treat cause; uncertain long-term benefit; dosing errors,; uncertain benefit (haemorrhage) | Constricts capacitance vessels; used in airway management / TBI with hypotension |
Benefits of reducing and immobilising a fracture, adapted from [14]
| Reduced pain | |
| Reduced blood loss | |
| Minimised neurovascular complications | |
| Reduced risk of fat embolism | |
| Reduced risk of further tissue damage; facilitated healing | |
| Easier transport |
Systemic analgesics, adapted from [180]. LOE denotes level of evidence in parentheses, provided if available. COX cyclooxygenase, mcg micrograms, mg milligrams, g grams, kg kilograms, mL milliliters, IV intravenous, IM intramuscular IN intranasal, NSAIDS nonsteroidal anti-inflammatory drugs, OTFC: oral transmucosal fentanyl citrate, po: by mouth, q: ‘every,’ qd: daily, bid: twice daily, tid: three times daily
| AGENT/DOSE SITE | DOSAGE ADULTS/(PEDS); LOE | REMARKS |
|---|---|---|
| 1B | Simple, noninvasive; reduces inflammation/oedema; avoid freezing injury [ | |
| 1A | All NSAIDS: if po, potential dyspepsia lessened with food. Avoid with GI bleed/ulcer history, dehydration. Possible kidney injury or increased bleeding | |
| Diclofenac topical | 2.3% topical; 2-4 g bid; unknown | |
| Ibuprofen PO | 2400 mg/d divided tid (10 mg/kg/d); 1A | |
| Naproxen PO | 660 mg/d divided tid; unknown | |
| Meloxicam PO | 15 mg qd; unknown | Cardiovascular events may increase. COX-2 selective inhibitor meloxicam minimises bleed/platelet disfunction. |
| Ketorolac IM | 60 mg q 6 h (0.5 mg/kg q6h); 2C | |
| IV | 15-30 mg (0.5 mg/kg, max 15 mg); 1B | |
| Paracetamol PO | Max 1300 mg (10 mg/kg) TID; 1B | Renal and GI sparing. Avoid in severe hepatic disease. Overdose can result in hepatic failure [ |
| IV | > 50 kg:1 g < 50 kg:15 mg/kg IV/15 min; 1B | |
| All opioids tend to cause respiratory depression/desaturation and arterial hypotension; monitor. Avoid opioids if patient needs full cognition (i.e. self-evacuation). Naloxone reverses opioids [ | ||
| Fentanyl IV | 25-100 mcg (1-3 mcg/kg); 1A | Slow fentanyl push mitigates risk of ‘frozen chest.’ |
| IN | 180 mcg (1.5 mcg/kg); 1B | |
| Buccal/transmucosal | OTFC: 800 mcg (10-15 mcg/kg); 1B | Oral transmucosal fentanyl citrate self-administered, ideal for austere situation. Transdermal route good for sustained dosing. |
| Transdermal | Transdermal route good for sustained dosing. | |
| Morphine IV | 5-10 mg (0.1 mg/kg-max 10 mg); 1A | Avoid morphine in renal failure. May cause histamine release. |
| IM | 10-20 mg (0.2 mg/kg, ma× 10 mg); 2B | Poor blood flow may limit absorption. |
| Oxycodone PO | 5-10 mg q8 h; 2B | PO opioids easy to carry on smaller expeditions. |
| Ketamine | 1B | Use half dose for S-ketamine. Slower administration lessens emesis and psychosis. Can cause hypertension and tachycardia; preserves respiration; many prefer for multiple trauma. Vocal calming measures and adding midazolam minimise psychosis [ |
| IV | 10-30 mg (0.1-0.3 mg/kg); 1B | |
| IM | 1 mg/kg; 2C | |
| IN | 0.5 mg/kg (0.5 mg/kg); 2B | |
| Methoxyflurane Inhaled | 3 mL given to self; max 6 mL/day; 2A | Altitude use. No renal effects; avoided by some; anxiolysis [ |
| Nitrous Oxide nhaled | 60-70% N2O/40-30% O2; 2B | Less effective at altitude, complex; potentiates barotrauma! |
Regional blocks appropriate for wilderness are listed below, adapted from [180], LOE denotes level of evidence
| Regional block | Indications | LOE | Remarks |
|---|---|---|---|
| Intra-articular injection | Shoulder dislocation | 2B | Not superior to procedural sedation [ |
| Intrascalene nerve block | Shoulder/arm injuries | 1C | Phrenic nerve paralysis and respiratory compromise (not ideal for altitude) [ |
| Supra- or infraclavicular block | Pathology distal to shoulder | 1B | Small ultrasound probe; 20-25 mL local anaesthetic, pneumothorax |
| Axillary block | Pathology distal to shoulder | 1C | Less anesthetic needed with ultrasound (~ 15 mL) [ |
| Median/ulnar/radial block | Distal forearm/hand/multiple | 1C | Nerves of mid-forearm readily seen with ultrasound; 3-5 mL [ |
| Intercostal nerve block | Isolated rib fracture(s) | 1C | Ideal if cardiorespiratory status with systemic analgesia worrisome [ |
| Femoral nerve block | Femur fracture/pathology | 1C | Not effective for posterior limb, or distal leg |
| 3-in 1 block | Femur/knee or distal extremity | 1C | For thigh and distal extremity/foot; lateral femoral cutaneous- femoral and obturator nerve [ |
| Fascia Iliaca block | Femur fracture/pathology | 1C | 90% success rate prehospital, simple; less injury risk to nerves; ~ 30 mL [ |
| Sciatic nerve block | Posterior thigh/knee/distal lower extremity | 1C | With femoral and saphenous nerve block, good for knee and distal lesions [ |
| Ankle nerve block | Ankle/foot | 2B | Need to block 5 nerves; high failure rate, good for isolated foot lacerations |
Different sites for temperature measurement, advantages and disadvantages for field use [200]
| Advantages | Disadvantages | Suitability for prehospital use | Logistic considerations | Field tested | |
|---|---|---|---|---|---|
| Noninvasive | Low correlation with core temperature | High | Skin temperature affected by environment, e.g. cold or wet | Yes (experimental animal model) | |
| Minimally invasive. Correlates with brain temperature | Influenced by ambient temperature and insulation of ear canal. Affected if ear canal contains water or snow [ | Moderate-high | Insulation of the external auditory canal improves the reliability of the reading. Thermistor technology ideal; infrared technology not reliable | Yes | |
| Commonly used in hospital | Lags behind core temperature when rewarming | Moderate | Needs to be inserted deeply (> 15 cm) to avoid measuring temperature of cold feces | Yes | |
| Allows to monitor urinary output | Can be affected by cold diuresis. Impractical for field use | Low | Mostly monitor based probes | No | |
| Best correlation with core temperature | Requires an advanced airway in place. Needs to be positioned in lower third of oesophagus for reliability | Moderate | Mostly monitor based (only one hand-held device) | Yes |
Fig. 2Use of ultrasound in multiple trauma patients and grading of evidence. ONSD denotes optic nerve sheath diameter